Ceftobiprole Medocaril Free Acid
The free acid form of the prodrug ceftobiprole medocaril is converted to the active ceftobiprole, a fifth-generation cephalosporin with activity against MRSA, Pseudomonas, and other pathogens. It is approved for hospital-acquired and community-acquired pneumonia. Its dual activity against MRSA and gram-negative bacteria including Pseudomonas fills an important therapeutic gap.
Peso molecular
690,7000 g/mol
LogP
0,40
TPSA
310,00 Ų
Regla de cinco de Lipinski
No cumple
Mecanismo de acción
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Estructura 2D
Cite this structure
Embed this structure
SMILES
Cc1oc(=O)oc1COC(=O)N1CC[C@@H](N2CC/C(=C\C3=C(C(=O)O)N4C(=O)[C@@H](NC(=O)/C(=N/O)c5nsc(N)n5)[C@H]4SC3)C2=O)C1
InChI
InChI=1S/C26H26N8O11S2/c1-10-14(45-26(41)44-10)8-43-25(40)32-4-3-13(7-32)33-5-2-11(20(33)36)6-12-9-46-22-16(21(37)34(22)17(12)23(38)39)28-19(35)15(30-42)18-29-24(27)47-31-18/h6,13,16,22,42H,2-5,7-9H2,1H3,(H,28,35)(H,38,39)(H2,27,29,31)/b11-6+,30-15+/t13-,16-,22-/m1/s1
Molecular Formula
C26H26N8O11S2
HBD / HBA
4 / 17
Enlaces Rotables
9
Átomos Pesados
47
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
The free acid form of the prodrug ceftobiprole medocaril is converted to the active ceftobiprole, a fifth-generation cephalosporin with activity against MRSA, Pseudomonas, and other pathogens. It is approved for hospital-acquired and community-acquired pneumonia. Its dual activity against MRSA and gram-negative bacteria including Pseudomonas fills an important therapeutic gap.
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Yes, Ceftobiprole Medocaril Free Acid is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1652606. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 135413544. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="ceftobiprole-medocaril-free-acid"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/ceftobiprole-medocaril-free-acid/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/ceftobiprole-medocaril-free-acid/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/ceftobiprole-medocaril-free-acid/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="ceftobiprole-medocaril-free-acid"></drugfyi-drug>